Skip to content
Triangle logo TriangleGet started
← recurrent Childhood Non-Hodgkin Lymphoma

NCT00939770 · STUDY IN CONTEXT

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Draft scope assessment: unclear. Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full. Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.

Phase 1 patients

→

primary · POSTED

The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.

All patients included in analysis

→

primary · POSTED

Mean with standard deviation of peak of serum concentration curve at steady state by dose level.

Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose

→

primary · POSTED

Mean with standard deviation of average serum concentration curve at steady state by dose level.

Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose

→

primary · POSTED

Mean with standard deviation of area under the serum concentration curve at steady state by dose level.

Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose

→

primary · POSTED

Mean with standard deviation of the elimination of crizotinib at steady state by dose level.

Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record
trial
release id
clinical-indications-draft-1
disease state id
ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
nct id
NCT00939770
trial label
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
applicability
unclear
applicability note
Attached because the study's own record describes recurrent disease. The study was not selected for this indication by its sponsor, and its eligibility has not been reconciled against this page in full.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
provenance class
regulator-cited
discovery note
Found because this study's registry identifier is printed in an FDA approval notice, an FDA product label or an NCI summary held by this site. The citing document and the exact position of the identifier inside it are recorded. Being cited is not a statement that the study supports this treatment.
outcome Count
6
harms Count
8
qol Count
0
outcomes
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0000
    source section id
    NCT00939770-om-0000
    source outcome index
    0
    endpoint
    Maximum-tolerated Dose and Recommended Phase 2 Dose of Crizotinib
    endpoint definition
    The descriptions and grading scales found in the revised National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for adverse event (AE) reporting. The MTD/RP2D is defined as the maximum dose at which fewer than one-third of patients experience dose limiting toxicity.
    time origin
    28 days
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Phase 1 patients
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    source section id
    NCT00939770-om-0001
    source outcome index
    1
    endpoint
    Number of Participants With Toxicities of Crizotinib
    endpoint definition
    The descriptions and grading scales found in the revised NCI CTCAE version 4.0 will be utilized for AE reporting.
    time origin
    Up to 30 days post-treatment
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    All patients included in analysis
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0002
    source section id
    NCT00939770-om-0002
    source outcome index
    2
    endpoint
    Steady State C Max of Crizotinib
    endpoint definition
    Mean with standard deviation of peak of serum concentration curve at steady state by dose level.
    time origin
    Cycle 1 (day 15- 28) pre-dose, 1, 2,4, 6-8 hours post dose
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0003
    source section id
    NCT00939770-om-0003
    source outcome index
    3
    endpoint
    Steady State C Average of Crizotinib
    endpoint definition
    Mean with standard deviation of average serum concentration curve at steady state by dose level.
    time origin
    Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0004
    source section id
    NCT00939770-om-0004
    source outcome index
    4
    endpoint
    Steady State AUC of Crizotinib
    endpoint definition
    Mean with standard deviation of area under the serum concentration curve at steady state by dose level.
    time origin
    Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hours post-dose
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0005
    source section id
    NCT00939770-om-0005
    source outcome index
    5
    endpoint
    Steady State Clearance of Crizotinib
    endpoint definition
    Mean with standard deviation of the elimination of crizotinib at steady state by dose level.
    time origin
    Cycle 1 (day 15-28) pre-dose, 1, 2, 4, 6-8 hour post-dose
    analysis role
    primary
    reporting status
    POSTED
    data cutoff
    Source null
    population note
    Steady state PK sampling was not performed during enrollment on dose level 1 or 2. In Phase 2, PK was optional and for those who consented data is included with dose level 5. Steady state PK samples were obtained on a day between day 15 and 28 of cycle 1, pre-dose, 1, 2, 4, 6-8 h post-dose.
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
arms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0000
    arm key
    OG000
    arm label
    Part A
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    98
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0000#groups/OG000
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG000
    arm label
    Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    6
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG000
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG001
    arm label
    Phase 1: Part A:PF-02341066 130 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    8
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG001
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG002
    arm label
    Phase 1: Part A:PF-02341066 165 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    23
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG002
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG003
    arm label
    Phase 1: Part A:PF-02341066 215 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    12
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG003
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG004
    arm label
    Phase 1: Part A:PF-02341066 280 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    38
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG004
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG005
    arm label
    Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID
    regimen
    Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
    analyzed count
    11
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG005
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG006
    arm label
    Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID
    regimen
    Part B: Patients with ALK+ relapsed/refractory neuroblastoma
    analyzed count
    14
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG006
  9. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0001
    arm key
    OG007
    arm label
    Phase 2:Part C: PF-02341066 280 mg/m2/Dose BID
    regimen
    Part C: Patients with ALK+ relapsed/refractory ALCL
    analyzed count
    10
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0001#groups/OG007
  10. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0002
    arm key
    OG000
    arm label
    Dose Level 3
    regimen
    PF-02341066 165 mg/m²/dose BID
    analyzed count
    1
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0002#groups/OG000
  11. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0002
    arm key
    OG001
    arm label
    Dose Level 4
    regimen
    PF-02341066 215 mg/m²/dose BID
    analyzed count
    5
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0002#groups/OG001
  12. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    outcome key
    om-0002
    arm key
    OG002
    arm label
    Dose Level 5
    regimen
    PF-02341066 280 mg/m²/dose BID
    analyzed count
    36
    analyzed unit
    Participants
    is comparator
    Source null
    source pointer
    NCT00939770-om-0002#groups/OG002
harms
  1. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG000
    source section id
    NCT00939770-ae
    event group key
    EG000
    event group label
    Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID
    serious affected
    3
    serious at risk
    6
    other affected
    6
    other at risk
    6
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  2. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG001
    source section id
    NCT00939770-ae
    event group key
    EG001
    event group label
    Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID
    serious affected
    6
    serious at risk
    8
    other affected
    8
    other at risk
    8
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  3. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG002
    source section id
    NCT00939770-ae
    event group key
    EG002
    event group label
    Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID
    serious affected
    18
    serious at risk
    23
    other affected
    23
    other at risk
    23
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  4. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG003
    source section id
    NCT00939770-ae
    event group key
    EG003
    event group label
    Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID
    serious affected
    10
    serious at risk
    12
    other affected
    12
    other at risk
    12
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  5. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG004
    source section id
    NCT00939770-ae
    event group key
    EG004
    event group label
    Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID
    serious affected
    33
    serious at risk
    38
    other affected
    38
    other at risk
    38
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  6. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG005
    source section id
    NCT00939770-ae
    event group key
    EG005
    event group label
    Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID
    serious affected
    11
    serious at risk
    11
    other affected
    11
    other at risk
    11
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  7. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG006
    source section id
    NCT00939770-ae
    event group key
    EG006
    event group label
    Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID
    serious affected
    13
    serious at risk
    14
    other affected
    14
    other at risk
    14
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
  8. release id
    clinical-indications-draft-1
    disease state id
    ds-non-hodgkin-lymphoma-pediatric-recurrent-c5218487
    nct id
    NCT00939770
    harm key
    EG007
    source section id
    NCT00939770-ae
    event group key
    EG007
    event group label
    Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID
    serious affected
    10
    serious at risk
    10
    other affected
    10
    other at risk
    10
    frequency threshold
    0
    collection period
    Up to 3 years
    event definition
    Adverse event reporting is collected routinely using case report forms. The SAE table reflects NCI Common Terminology Criteria for Adverse Events (CTCAEs) submitted by the institution, via expedited reporting (NCI AdEERs / CAeRs). The "AE Other" table reflects all CTCAEs collected excluding those that were reported as SAEs. Ineligible patients are excluded from reporting of adverse events. All-Cause Mortality includes all deaths collected on the study.
    undenominated note
    Source null
    curation status
    draft
    reviewed by
    Source null
    reviewed at
    Source null
    created at
    2026-09-10T00:00:00Z
quality of life
    setting source links

      Preserved source evidence · Not medical advice